Disease Markers

Disease Markers / 2019 / Article
Special Issue

Find the Essence through the Phenomena: Cardiovascular Diseases and Biomarkers 2019

View this Special Issue

Research Article | Open Access

Volume 2019 |Article ID 2568069 | 9 pages | https://doi.org/10.1155/2019/2568069

Links between High-Sensitivity C-Reactive Protein and Pulse Wave Analysis in Middle-Aged Patients with Hypertension and High Normal Blood Pressure

Academic Editor: Zhongjie Shi
Received23 Feb 2019
Accepted13 Jun 2019
Published17 Jul 2019

Abstract

Arterial stiffness and arterial age provide valuable prognostic cardiovascular information. The present study aimed at assessing the levels of vitamin D, high-sensitivity C-reactive protein (hsCRP), low-density lipoprotein cholesterol (LDL), and oxidized LDL (oxLDL) in a group of middle-aged hypertensive patients and their relationship with pulse wave velocity (PWV), central blood pressure, and early arterial aging (EAA), respectively. A total of 56 patients, aged , 57% males, with hypertension and high normal blood pressure (HNBP), were investigated using a Mobile-O-Graph, to assess central and peripheral blood pressure, PWV, and arterial age. Additionally, hsCRP, LDL, oxLDL, and 25-hydroxy vitamin D3 were assessed. PWV, 25-hydroxy vitamin D3, hsCRP, oxLDL, and LDL levels were , , , , and , respectively. Significant correlations were obtained between oxLDL and pulse pressure amplification (, ) and between hsCRP and LDL levels with PWV and EAA, respectively. ROC curve analysis revealed that hsCRP is a sensitive and specific predictor of EAA and increased PWV values. Concluding, vitamin D deficiency and increased hsCRP and LDL values are very common, and high oxidized LDL is related to pulse pressure amplification in patients with elevated blood pressure. Vitamin D level and high-sensitivity C-reactive protein and LDL provide valuable information in middle-aged hypertensive and HNBP patients related to arterial stiffness and early arterial aging, but only hsCRP is a sensitive predictor of EAA and PWV.

1. Introduction

Cardiovascular disorders are leading causes of death worldwide, and Romania was considered a high-cardiovascular-risk country according to the guidelines of the European Society of Cardiology [1]. Early detection of cardiovascular risk and subclinical atherosclerosis should represent a priority, along with the detection of new cardiovascular active substances. Arterial stiffness and arterial age provide valuable prognostic cardiovascular information [2]. Arterial stiffness, the expression of impaired arterial elasticity, may be assessed using pulse wave velocity (PWV) or the augmentation index (AI). AI is a wave reflection parameter and an indirect biomarker of arterial stiffening [3, 4], while arterial age represents the chronological age of a person with all risk factors at normal levels and the same 10-year predicted risk [5].

Vitamin D is essential not just for musculoskeletal health, considering that low 25-hydroxy vitamin D levels were frequently associated with an increased risk of cardiovascular events, including stroke and heart failure [69]. C-reactive protein, an acute phase reactant and a marker of chronic low-grade inflammation, can predict cardiovascular events and was mentioned as the only circulating biomarker related to vascular wall biology [3, 10, 11]. High-sensitivity CRP (hsCRP) is a better predictor of vascular disorders than CRP. LDL cholesterol and oxidized LDL favor the formation of the foam cells and the development of the atherosclerotic plaque. There is a continuous relationship between blood pressure and cardiovascular events, and diagnosis of hypertension also requires evaluation of cardiovascular risk factors.

Considering the importance of prophylactic measures in hypertension, the present study aimed at assessing the levels of several laboratory biomarkers such as vitamin D, high-sensitivity C-reactive protein, LDL, and oxidized LDL (oxLDL) and their impact on pulse wave velocity, central blood pressure, and early arterial aging (EAA), respectively, in a group of middle-aged patients with hypertension and high normal blood pressure.

2. Materials and Methods

2.1. Study Population

A total of 56 consecutive hypertensive and HNBP patients, recruited from the Military Hospital Timisoara, were investigated during the period of July 2016–March 2017. All patients underwent investigation using a Mobil-O-Graph, and biochemical measurements were performed on the same day. Data about cardiovascular risk factors, diagnosis, and therapy were collected from medical records.

Patients aged between 18 and 55 years, with essential hypertension, both treated as well as uncontrolled patients, and high normal blood pressure, were included. Essential hypertension and high normal blood pressure were diagnosed according to the European criteria [12]. Cardiovascular risk in hypertensive patients was evaluated according to the criteria of the European Society of Cardiology, considering the number of cardiovascular risk factors, hypertension-mediated organ damage, and chronic kidney disease [12]. Patients with secondary hypertension, atrial fibrillation, diabetes mellitus, history of coronary heart disease, myocardial infarction, stroke, transient ischemic attack or peripheral arterial disease, systemic inflammatory processes, active infections, trauma, and therapy with statins were excluded.

The investigations conformed to the principles outlined in the Declaration of Helsinki and were approved by the “Victor Babes” University. Written informed consent was obtained from each study participant, and the objectives and procedures of the study were explained to each patient included in the study.

2.2. Biochemical Measurements

Blood was drawn after an overnight fast. Serum levels of 25-hydroxy-cholecalciferol, high-sensitivity C-reactive protein, LDL, and oxidized LDL were measured. LDL was assessed using a photometric method, a Siemens Advia 1800 analyzer, and Siemens LDL cholesterol reagents. An ELISA method and Immundiagnostik reagents were used for oxidized LDL. 25-Hydroxy-cholecalciferol and high-sensitivity C-reactive protein were assessed using liquid chromatography and immunophelometry, respectively. The thresholds used for defining normal/abnormal values for the various laboratory variables were provided by the laboratory.

2.3. Mobil-O-Graph

Pulse wave velocity (PWV), augmentation index and pressure (AI, AP), arterial (vascular) age, and central and peripheral blood pressure were assessed using a Mobil-O-Graph (IEM GmbH, Stolberg, Germany), a noninvasive, validated device.

The measurements were made after 10 minutes of rest, in supine position, using different cuff sizes, and considering the arm circumference. The participants were not allowed to smoke, eat, or drink coffee or alcohol 4 hours before the recording and speak or move during the measurements.

Mobil-O-Graph enables brachial blood pressure measurement, followed by the reinflation of the cuff and recording of pulse waves, with a high-fidelity pressure sensor [13]. After measuring systolic, diastolic, and mean arterial pressure, the software enabled the reconstruction of the aortic pulse wave using a generalized transfer function [13]. Wave separation analysis enabled decomposing the aortic pulse wave into forward-traveling (incident) and backward-traveling (reflected) pulse waves and allowed calculating the augmentation pressure (AP), augmentation index (AI), and PWV. AP was assessed as the difference in pressure of the reflected wave minus pressure of the forward-traveling wave of the systolic phase of the pulse wave [13]. Central systolic blood pressure (cSYS), central diastolic blood pressure (cDIA), and central pulse pressure (cPP) were also calculated by the device.

AI was defined as the ratio of AP to aortic pulse pressure, indicating the augmentation component of aortic SBP due to the premature arrival of the reflected wave [13]. PWV was estimated from the reconstructed aortic pulse waveform via mathematical models, considering impedance and age [13].

The significance of the variables was also described in previous studies [14]. PWV and AI were considered increased if they exceeded the normal values for the patients’ ages according to the device manufacturer, and pathological values were shown by the device (Figure 1). Pulse pressure amplification, defined as cPP/PP [15], was calculated separately. Early arterial aging was considered when arterial age was higher than the biological age.

2.4. Statistical Analysis

Categorical data are given as numbers and percentages; continuous data are given as . Bravais-Pearson’s, Kendall’s, and Spearman’s correlations and ROC curve analysis were used as statistical methods. Nonparametric correlations were used especially for assessing the correlation between a dichotomous variable and a continuous variable. Analyses were performed using IBM SPSS Base Edition.

3. Results

3.1. Characteristics of the Study Population

The subjects included in the study were middle-aged (), and most of them were male (57%). The baseline characteristics of the study population are included in Table 1.


Characteristics

Age (years)

Gender (male)32 (57%)

BMI (kg/m2)

SBP (mmHg)

DBP (mmHg)

MAP (mmHg)

Heart rate (beats/minute)

PP (mmHg)

cSYS (mmHg)

cDIA (mmHg)

cPP (mmHg)

TVR ()

Augmentation pressure (mmHg)

Augmentation index (AI) (%)

Pulse wave velocity (PWV) (m/s)

PWV increased for age (pathological PWV)12 (21.4%)

Early arterial aging18 (32.1%)

Family history of cardiovascular disorders13 (22.5%)

Cardiovascular riskHigh: 17 (30%)
Low: 14 (25%)

Hypertension (HT)High normal: 21 (37.5%)
HT grade 1: 16 (28.6%)
HT grade 2: 13 (23.2%)
HT grade 3: 6 (10.7%)

TherapyACEI: 17 (30%)
Sartans: 10 (17.5%)
Diuretics: 18 (32.5%)
Beta blockers: 18 (32.5%)
Calcium channel blockers: 4 (7.5%)

BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood pressure; MAP=mean arterial pressure; PP=pulse pressure; cSYS=central systolic blood pressure; cDIA=central diastolic blood pressure; cPP=central pulse pressure; TVR=total vascular resistance; ACEI=angiotensin converting enzyme inhibitors; HT=hypertension.

Vitamin D deficiency and insufficiency, defined as and <30 microg/l, respectively, were very common in the study population, as well as increased hsCRP and LDL values (Table 2). Vitamin D deficiency and insufficiency were defined according to the reference values provided by the laboratory.


Biomarker

Vitamin D (microg/l)
19 (34%)
41 (73%)
hsCRP (mg/dl)
43 (77%)
29 (52%)
LDL (mg/dl)
49 (88%)
35 (62.5%)
17 (30%)
Oxidized LDL (ng/ml)

LDL=low-density lipoprotein; hsCRP=high-sensitivity C-reactive protein.
3.2. Correlations

Correlations were calculated for all variables mentioned in the study objectives, both in a continuous fashion and after categorization. However, no significant correlations were obtained between vitamin D level and pulse wave and blood pressure variables. High-sensitivity C-reactive protein was significantly correlated with early arterial aging, PWV, and pulse pressure amplification (Table 3). LDL cholesterol levels correlated with central systolic and diastolic blood pressure, PWV values, and pulse pressure amplification (Table 3). No significant correlations were obtained between cardiovascular risk (low to very high) assessed according to the criteria of the European Society of Cardiology [12] and vitamin D level, high-sensitivity C-reactive protein, LDL cholesterol levels, and oxidized LDL.


Correlated variablesCorrelation coefficient

hsCRP-EAA0.004
0.003
0.002
hsCRP-PWV0.016
0.021
hsCRP-pPWV0.002
0.004
hsCRP-EAA0.007
CRP100-PWV0.031
0.032
0.031
CRP100-cPP/PP0.031
CRP100-EAA0.031
CRP300-PWV0.008
0.002
0.001
CRP300-EAA0.007
0.008
0.007
LDL100-PWV0.022
LDL130-cSYS0.020
0.028
0.026
LDL130-cDIA0.039
LDL130-PWV0.023
LDL130-cPP/PP0.033
oxLDL-cPP/PP0.042
0.028

rP=Bravais-Pearson’s correlation coefficient; rK=Kendall’s correlation; rS=Spearman’s correlation; cPP/PP=pulse pressure amplification; EAA=early arterial aging; PWV=pulse wave velocity; pPWV=pathological pulse wave velocity (increased for age); cSYS=central systolic blood pressure; cDIA=central diastolic blood pressure; hsCRP=high-sensitivity C-reactive protein; CRP100=high-sensitivity C-reactive protein exceeding 0.100 mg/dl; CRP300=; LDL100=; LDL130=; LDL160=; oxLDL=oxidized LDL.
3.3. Receiver-Operating Characteristic (ROC) Curve Analysis, Sensitivity, Specificity, and Positive and Negative Predictive Values

ROC curve analysis revealed hsCRP as a sensitive and specific test for EAA and pPWV (Figures 2 and 3). The cut-off value for hsCRP was higher for predicting an increased pulse wave velocity than early arterial aging (Table 4).


Test variableState variableAUC (95% CI)Cut-off valueSensitivitySpecificity

hsCRPEAA0.749 (0.607-0.890)0.0030.38883.3%71.1%
hsCRPpPWV0.766 (0.603-0.929)0.0050.44683.3%65.6%

EAA=early arterial aging; PWV=pulse wave velocity; pPWV=pathological pulse wave velocity (increased for age).

Vitamin D, LDL, and oxidized LDL were not revealed as sensitive markers for EAA or PWV according to ROC curve analysis (Table 5).


Test variableState variableAUC (95% CI)

Vitamin DpPWV0.473 (0.274-0.673)0.78
Vitamin DEAA0.487 (0.324-0.65)0.875
LDLpPWV0.393 (0.227-0.559)0.259
LDLEAA0.45 (0.291-0.608)0.545
oxLDLpPWV0.547 (0.314-0.78)0.685
oxLDLEAA0.484 (0.292-0.676)0.874

pPWV=pathological pulse wave velocity (increased for age); EAA=early arterial aging; LDL=low-density lipoprotein; oxLDL=oxidized LDL.

Further testing revealed important negative predictive values for low vitamin D, oxidized LDL, and hsCRP levels in predicting pathological PWV values and for hsCRP in predicting EAA (Table 6). Oxidized LDL showed good specificity in predicting PWV and EAA, and high-sensitivity C-reactive protein exceeding 0.100 mg/dl, also a good specificity (Table 6).


Test variablesSensitivity (95% CI)Specificity (95% CI)Positive predictive value (PPV) (95% CI)Negative predictive value (NPV) (95% CI)

D20-pPWV0.363 (0.123-0.683)0.666 (0.509-0.795)0.21 (0.069-0.46)0.81 (0.642-0.914)
D20-EAA0.333 (0.143-0.588)0.657 (0.485-0.798)0.315 (0.135-0.565)0.675 (0.501-0.814)
LDL160-pPWV0.055 (0.002-0.293)0.605 (0.434-0.755)0.062 (0.003-0.322)0.575 (0.41-0.725)
LDL160-EAA0.166 (0.04-0.422)0.631 (0.459-0.777)0.176 (0.046-0.441)0.615 (0.446-0.761)
oxLDL-pPWV0.25 (0.044-0.644)0.843 (0.664-0.941)0.285 (0.051-0.697)0.818 (0.639-0.923)
oxLDL-EAA0.153 (0.027-0.463)0.814 (0.612-0.929)0.285 (0.051-0.697)0.666 (0.481-0.814)
CRP100-pPWV0.833 (0.508-0.97)0.272 (0.154-0.43)0.238 (0.125-0.398)0.857 (0.561-0.974)
CRP100-EAA0.944 (0.706-0.997)0.315 (0.18-0.487)0.395 (0.253-0.555)0.923 (0.62-0.995)
CRP300-pPWV0.75 (0.428-0.933)0.545 (0.389-0.693)0.31 (0.159-0.509)0.888 (0.697-0.97)
CRP300-EAA0777 (0.519-0.926)0.605 (0.434-0.755)0.482 (0.298-0.671)0.851 (0.653-0.951)

pPWV=pathological pulse wave velocity (increased for age); EAA=early arterial aging; oxLDL=oxidized LDL; LDL160=LDL > 160 mg/dl; CRP100=high-sensitivity C-reactive protein exceeding 0.100 mg/dl; CRP300=high-sensitivity C-reactive protein > 0.300 mg/dl; D20=vitamin D < 20 microg/l. The highest values for sensitivity, specificity, and NPV are in bold.

4. Discussion

The present study reports that low vitamin D levels and increased hsCRP and LDL values are very common in middle-aged hypertensive and HNBP patients; correlations were also found between pulse wave velocity and early arterial aging with high-sensitivity C-reactive protein and LDL cholesterol levels, respectively. However, only hsCRP was found as a sensitive predictor of early arterial aging.

Conflicting results have been previously published regarding the relationship between vitamin D level, vitamin D supplementation, and arterial stiffness [16, 17]. Several studies revealed associations between vitamin D level and PWV [1821], but other authors found no significant association between vitamin D concentrations and markers of subclinical atherosclerosis [22, 23]. The present study found no significant correlation between vitamin D level and PWV but revealed a good negative predictive value of vitamin D level for pathological PWV values. The link between vitamin D deficiency and hypertension can be explained by the activation of the renin-angiotensin-aldosterone system, increasing the vascular tone due to the release of angiotensin II [24]. Vitamin D is also involved in the downregulation of the renin gene expression [25]. Vitamin D has also pleiotropic effects on the immune system and suppresses the low-grade inflammation in the cardiovascular system [17, 26]. Other important pathophysiological vasculoprotective mechanisms by which vitamin D supplementation reduces arterial stiffness include improvement of the endothelial function, suppression of endothelin-induced vascular smooth muscle cell proliferation, effects on calcium metabolism and PTH level, counterbalancing of oxidative stress, and improvement of carbohydrate metabolism and insulin sensitivity [2733]. Related to oxidative stress, vitamin D activates several genes encoding for antioxidant and detoxifying enzymes [25]. The accumulation of calcium in the vessel walls increases arterial tone and arterial stiffness in hypertension [34]. However, no significant correlations were obtained in our study between vitamin D level and hsCRP or oxidized LDL, respectively.

25-Hydroxy vitamin D and not 1,25-dihydroxy vitamin D was assessed in the present study because 25-hydroxy vitamin D is a nutritional parameter of vitamin D status, the primary circulating and storage form of vitamin D, and a reliable, available marker of low vitamin D levels able to bind to vitamin D receptors [18, 35].

Several mechanisms link inflammation and arterial stiffness, considering the effect of inflammation on the arterial endothelium, nitric oxide (NO), and smooth muscle cells and considering its ability to change the composition of the extracellular matrix, to breakdown elastin, and to enable the calcification of the vessel wall [36]. hsCRP was associated with arterial stiffness in some studies [3, 3740], but other studies did not find any association [41]. Kim et al. reported significant associations between hsCRP and arterial stiffness independent of age, systolic blood pressure, gender, heart rate, glucose, lipid profiles, and therapy in treated hypertension [38]. The present study found significant correlations and associations between hsCRP and PWV, EAA and pulse pressure amplification, respectively. High-sensitivity C-reactive protein was the only sensitive predictor of early arterial aging and elevated PWV, with a higher cut-off value for predicting increased pulse wave velocity than early arterial aging (0.446 vs. 0.388). Significant correlations were obtained in the present study between hsCRP and LDL130 (exceeding 130 mg/dl) (, ; , ). High-sensitivity C-reactive protein, a marker of low-grade inflammation, was also associated with deep white matter lesions, ischemic stroke, and heart failure [42, 43]. On the other hand, arterial stiffness was significantly associated with ischemic stroke after adjusting for cardiovascular risk factors [44].

Non-HDL cholesterol was reported as a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population [45]. Kim et al. reported a modest increase in arterial stiffness due to dyslipidemia only in women [46]. Increased LDL levels correlated with central systolic and diastolic blood pressure, PWV, and pulse pressure amplification in the present study, regardless of gender.

Oxidized LDL was associated with pulse wave velocity in patients with renal failure [47] and in healthy persons between 45 and 69 years old [48]; it was also associated with the augmentation index in obese children and adolescents [49]. In the present study, oxLDL correlated with pulse pressure amplification (, ). A high specificity and negative predictive value were obtained for oxidized LDL in predicting pathological PWV.

Pulse pressure amplification, the ratio between central and peripheral pulse pressure, is related to an increase of pulse pressure (PP) amplitude as pressure waves propagate distally in the vessel network and is a measure of arterial elasticity [50, 51]. Changes in PP amplification are associated with traditional cardiovascular risk factors, including hypertension [52]. In our study, oxLDL, elevated hsCRP, and LDL values significantly correlated with PP amplification.

The most important study limitations include the cross-sectional study design, which does not provide any data about the cause-effect relationship, the relatively small sample size, and not considering the duration of daily sun exposure, which is important for vitamin D synthesis. Further larger studies are needed to demonstrate if vitamin D level, hsCRP, LDL, and oxidized LDL play important roles in the development of increased arterial stiffness and early arterial aging in hypertensive patients and to reveal their relationship with cardiovascular events, such as stroke and heart failure in hypertensive patients. A power analysis, using PASS 2019, was conducted before the study to determine the sample size needed for the present study, and we do not expect changes in the results by increasing the sample size. A minimum sample size required for Bravais-Pearson’s and Spearman’s correlations was 35 participants (desired statistical power: 0.8; correlation coefficient: 0.4). The required sample size for an area under the curve (AUC) of 0.7 and power and alpha of 0.75 and 0.15, respectively, was 52. One reading was made for each study participant for PWV, AI, and AP using the Mobil-O-Graph, which might be considered as another study limitation; however, earlier measurements provided by the same device demonstrated good reproducibility. According to Table 1, average blood pressure values are not impressive (137/91 mmHg) and PWV is not very high (on average 7.26 m/s). However, the population is proper for the study purpose, considering that PWV was increased for age in 21.4% of the participants and high normal and grade 1-3 hypertension patients were included, with both high and low cardiovascular risks. The cut-off values for increased PWV were provided by the Mobil-O-Graph considering age, and they were lower than those recommended by the European Guidelines (a threshold of 10 m/s for pathological values) [53]. The latter should emphasize the prophylactic character of the present study.

Our study is the first one comparing the predictive value of vitamin D, LDL, oxidized LDL, and hsCRP for arterial stiffness and early arterial aging, demonstrating a high sensitivity only for hsCRP, and revealing, for the first time, as far as we know, a correlation between pulse pressure amplification and oxidized LDL level. The findings of the present study have clinical implications, considering the prognostic importance of increased arterial stiffness and early arterial aging for cardiovascular risk. hsCRP, LDL, and oxidized LDL can provide valuable information related especially to large vessels, arterial age, and cardiovascular risk in treated hypertensive patients.

Hypertension is a state of low vitamin D level, oxidative stress, and low-grade inflammation. Further larger follow-up studies are needed in hypertensive patients to confirm the findings of the present study and to correlate the collagen content of the arterial wall with vitamin D level, high-sensitivity C-reactive protein, LDL, and oxidized LDL level, in order to confirm their role as cardiovascular active substances.

5. Conclusions

Concluding, low vitamin D levels and increased hsCRP and LDL values are very common in middle-aged hypertensive and high normal blood pressure patients, and they provide, along with oxidized LDL, valuable information about vascular function. However, only high-sensitivity C-reactive protein level is a sensitive predictor of increased arterial stiffness and early arterial aging.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

A part of the data were presented as an abstract at the 8th International Congress of Pathophysiology, 2018. The founding sponsors had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

The present study was funded by the Bioclinica grant 9/2743/9.03.2016. No funds were received for covering the costs to publish in open access.

References

  1. M. F. Piepoli, A. W. Hoes, S. Agewall et al., “2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR),” Atherosclerosis, vol. 252, pp. 207–274, 2016. View at: Publisher Site | Google Scholar
  2. I. Mozos and C. T. Luca, “Crosstalk between oxidative and nitrosative stress and arterial stiffness,” Current Vascular Pharmacology, vol. 15, no. 5, pp. 446–456, 2017. View at: Publisher Site | Google Scholar
  3. C. Vlachopoulos, P. Xaplanteris, V. Aboyans et al., “The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society,” Atherosclerosis, vol. 241, no. 2, pp. 507–532, 2015. View at: Publisher Site | Google Scholar
  4. I. Mozos, “The link between ventricular repolarization variables and arterial function,” Journal of Electrocardiology, vol. 48, no. 2, pp. 145–149, 2015. View at: Publisher Site | Google Scholar
  5. H. Y. Lee and B. H. Oh, “Aging and arterial stiffness,” Circulation Journal, vol. 74, no. 11, pp. 2257–2262, 2010. View at: Publisher Site | Google Scholar
  6. T. J. Wang, M. J. Pencina, S. L. Booth et al., “Vitamin D deficiency and risk of cardiovascular disease,” Circulation, vol. 117, no. 4, pp. 503–511, 2008. View at: Publisher Site | Google Scholar
  7. I. Mozos and O. Marginean, “Links between Vitamin D Deficiency and Cardiovascular Diseases,” BioMed Research International, vol. 2015, 12 pages, 2015. View at: Publisher Site | Google Scholar
  8. I. Bressendorff, L. Brandi, M. Schou et al., “The effect of high dose cholecalciferol on arterial stiffness and peripheral and central blood pressure in healthy humans: a randomized controlled trial,” PLoS One, vol. 11, no. 8, article e0160905, 2016. View at: Publisher Site | Google Scholar
  9. M. Craciunescu, D. Stoian, A. Schiller et al., “Study on 25-hydroxy-vitamin D for the assessment of bone mineral density,” Revista de Chimie, vol. 67, no. 3, pp. 543–548, 2016. View at: Google Scholar
  10. G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., “The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina,” The New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994. View at: Publisher Site | Google Scholar
  11. P. M. Ridker, N. Rifai, L. Rose, J. E. Buring, and N. R. Cook, “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events,” The New England Journal of Medicine, vol. 347, no. 20, pp. 1557–1565, 2002. View at: Publisher Site | Google Scholar
  12. G. Mancia, R. Fagard, K. Narkiewicz et al., “2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” European Heart Journal, vol. 34, no. 28, pp. 2159–2219, 2013. View at: Publisher Site | Google Scholar
  13. A. Karpetas, P. A. Sarafidis, P. I. Georgianos et al., “Ambulatory recording of wave reflections and arterial stiffness during intra- and interdialytic periods in patients treated with dialysis,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 4, pp. 630–638, 2015. View at: Publisher Site | Google Scholar
  14. I. Mozos, J. Maidana, D. Stoian, and M. Stehlik, “Gender differences of arterial stiffness and arterial age in smokers,” International Journal of Environmental Research and Public Health, vol. 14, no. 6, p. 565, 2017. View at: Publisher Site | Google Scholar
  15. A. Benetos, F. Thomas, L. Joly et al., “Pulse Pressure Amplification: A Mechanical Biomarker of Cardiovascular Risk,” Journal of the American College of Cardiology, vol. 55, no. 10, pp. 1032–1037, 2010. View at: Publisher Site | Google Scholar
  16. A. J. Rodriguez, D. Scott, V. Srikanth, and P. Ebeling, “Effect of vitamin D supplementation on measures of arterial stiffness: a systematic review and meta-analysis of randomized controlled trials,” Clinical Endocrinology, vol. 84, no. 5, pp. 645–657, 2016. View at: Publisher Site | Google Scholar
  17. I. Mozos, D. Stoian, and C. T. Luca, “Crosstalk between vitamins A, B12, D, K, C, and E status and arterial stiffness,” Disease Markers, vol. 2017, 14 pages, 2017. View at: Publisher Site | Google Scholar
  18. A. R. Patange, R. P. Valentini, W. Du, and M. D. Pettersen, “Vitamin D deficiency and arterial wall stiffness in children with chronic kidney disease,” Pediatric Cardiology, vol. 33, no. 1, pp. 122–128, 2012. View at: Publisher Site | Google Scholar
  19. J. A. Reynolds, S. Haque, J. L. Berry et al., “25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus,” Rheumatology (Oxford, England), vol. 51, no. 3, pp. 544–551, 2012. View at: Publisher Site | Google Scholar
  20. R. Lieberman, R. P. Wadwa, N. Nguyen et al., “The association between vitamin D and vascular stiffness in adolescents with and without type 1 diabetes,” PLoS One, vol. 8, no. 10, article e77272, 2013. View at: Publisher Site | Google Scholar
  21. P. Jha, L. M. Dolan, P. R. Khoury, E. M. Urbina, T. R. Kimball, and A. S. Shah, “Low serum vitamin D levels are associated with increased arterial stiffness in youth with type 2 diabetes,” Diabetes Care, vol. 38, no. 8, pp. 1551–1557, 2015. View at: Publisher Site | Google Scholar
  22. M. C. Sachs, J. D. Brunzell, P. A. Cleary et al., “Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes,” Diabetes Care, vol. 36, no. 8, pp. 2423–2429, 2013. View at: Publisher Site | Google Scholar
  23. S. C. van Dijk, E. Sohl, C. Oudshoorn et al., “Non-linear associations between serum 25-OH vitamin D and indices of arterial stiffness and arteriosclerosis in an older population,” Age and Ageing, vol. 44, no. 1, pp. 136–142, 2015. View at: Publisher Site | Google Scholar
  24. I. Al Mheid, R. S. Patel, V. Tangpricha, and A. A. Quyyumi, “Vitamin D and cardiovascular disease: is the evidence solid?” European Heart Journal, vol. 34, no. 48, pp. 3691–3698, 2013. View at: Publisher Site | Google Scholar
  25. D. Caccamo, S. Ricca, M. Currò, and R. Ientile, “Health Risks of Hypovitaminosis D: A Review of New Molecular Insights,” International Journal of Molecular Sciences, vol. 19, no. 3, p. 892, 2018. View at: Publisher Site | Google Scholar
  26. E. K. Calton, K. N. Keane, P. Newsholme, and M. J. Soares, “The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies,” PLoS One, vol. 10, no. 11, p. e0141770, 2015. View at: Publisher Site | Google Scholar
  27. S. Chen, C. S. Law, and D. G. Gardner, “Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 118, no. 3, pp. 135–141, 2010. View at: Publisher Site | Google Scholar
  28. Y. Dong, I. S. Stallmann-Jorgensen, N. K. Pollock et al., “A 16-Week Randomized Clinical Trial of 2000 International Units Daily Vitamin D3 Supplementation in Black Youth: 25-Hydroxyvitamin D, Adiposity, and Arterial Stiffness,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4584–4591, 2010. View at: Publisher Site | Google Scholar
  29. D. Martins, Y.-X. Meng, N. Tareen et al., “The effect of short term vitamin D supplementation on the inflammatory and oxidative mediators of arterial stiffness,” Health, vol. 06, no. 12, pp. 1503–1511, 2014. View at: Publisher Site | Google Scholar
  30. K. J. Yun and K. H. Baek, “Is vitamin D supplementation really effective in patients with type 2 diabetes?” The Korean Journal of Internal Medicine, vol. 29, no. 5, pp. 574–576, 2014. View at: Publisher Site | Google Scholar
  31. A. Zaleski, G. Panza, H. Swales et al., “High-dose versus low-dose vitamin D supplementation and arterial stiffness among individuals with prehypertension and vitamin D deficiency,” Disease Markers, vol. 2015, 7 pages, 2015. View at: Publisher Site | Google Scholar
  32. A. Caraba, V. Crisan, I. Romosan, I. Mozos, and M. Murariu, “Vitamin D status, disease activity, and endothelial dysfunction in early rheumatoid arthritis patients,” Disease Markers, vol. 2017, 7 pages, 2017. View at: Publisher Site | Google Scholar
  33. G. Sypniewska, J. Pollak, P. Strozecki et al., “25-Hydroxyvitamin D, biomarkers of endothelial dysfunction and subclinical organ damage in adults with hypertension,” American Journal of Hypertension, vol. 27, no. 1, pp. 114–121, 2014. View at: Publisher Site | Google Scholar
  34. R. M. Touyz, R. Alves-Lopes, F. J. Rios et al., “Vascular smooth muscle contraction in hypertension,” Cardiovascular Research, vol. 114, no. 4, pp. 529–539, 2018. View at: Publisher Site | Google Scholar
  35. N. Chitalia, T. Ismail, L. Tooth et al., “Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients,” PLoS One, vol. 9, no. 3, article e91363, 2014. View at: Publisher Site | Google Scholar
  36. S. Jain, R. Khera, V. F. Corrales–Medina, R. R. Townsend, and J. A. Chirinos, “Inflammation and arterial stiffness in humans,” Atherosclerosis, vol. 237, no. 2, pp. 381–390, 2014. View at: Publisher Site | Google Scholar
  37. P. Kampus, J. Kals, T. Ristim??e, K. Fischer, M. Zilmer, and R. Teesalu, “High-sensitivity C-reactive protein affects central haemodynamics and augmentation index in apparently healthy persons,” Journal of Hypertension, vol. 22, no. 6, pp. 1133–1139, 2004. View at: Publisher Site | Google Scholar
  38. J. S. Kim, T. S. Kang, J. B. Kim et al., “Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients,” Atherosclerosis, vol. 192, no. 2, pp. 401–406, 2007. View at: Publisher Site | Google Scholar
  39. S. Park and E. G. Lakatta, “Role of inflammation in the pathogenesis of arterial stiffness,” Yonsei Medical Journal, vol. 53, no. 2, pp. 258–261, 2012. View at: Publisher Site | Google Scholar
  40. A. Nurizal, D. Antono, I. P. Wijaia, and H. Shatri, “Correlation between high-sensitivity C reactive protein and local arterial stiffness measured by radio frequency echotracking system in type 2 diabetic patients,” Acta Medica Indonesiana, vol. 46, no. 4, 2014. View at: Google Scholar
  41. H. Tomiyama, T. Arai, Y. Koji et al., “The relationship between high-sensitive C-reactive protein and pulse wave velocity in healthy Japanese men,” Atherosclerosis, vol. 174, no. 2, pp. 373–377, 2004. View at: Publisher Site | Google Scholar
  42. J. van Wezenbeek, J. M. Canada, K. Ravindra et al., “C-reactive protein and N-terminal pro-brain natriuretic peptide levels correlate with impaired cardiorespiratory fitness in patients with heart failure across a wide range of ejection fraction,” Frontiers in Cardiovascular Medicine, vol. 5, p. 178, 2018. View at: Publisher Site | Google Scholar
  43. H. Yao, Y. Mizoguchi, A. Monji et al., “Low-Grade Inflammation Is Associated with Apathy Indirectly via Deep White Matter Lesions in Community-Dwelling Older Adults: The Sefuri Study,” International Journal of Molecular Sciences, vol. 20, no. 8, p. 1905, 2019. View at: Publisher Site | Google Scholar
  44. E. Y. Yang, L. Chambless, A. R. Sharrett et al., “Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study,” Stroke, vol. 43, no. 1, pp. 103–108, 2012. View at: Publisher Site | Google Scholar
  45. R. O. Alvim, J. Mourão, G. L. Magalhães et al., “Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population,” Clinics, vol. 72, no. 2, pp. 106–110, 2017. View at: Publisher Site | Google Scholar
  46. J. Y. Kim, J. B. Park, D. S. Kim et al., “Gender difference in arterial stiffness in a multicenter cross-sectional study: the Korean arterial aging study (KAAS),” Pulse, vol. 2, no. 1-4, pp. 11–17, 2014. View at: Publisher Site | Google Scholar
  47. A. F. G. Cicero, M. Kuwabara, R. Johnson et al., “LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the Brisighella Heart Study cohort,” International Journal of Cardiology, vol. 261, pp. 204–208, 2018. View at: Publisher Site | Google Scholar
  48. M. Kim, M. Kim, H. J. Yoo, S. Y. Lee, S. H. Lee, and J. H. Lee, “Age-specific determinants of pulse wave velocity among metabolic syndrome components, inflammatory markers, and oxidative stress,” Journal of Atherosclerosis and Thrombosis, vol. 25, no. 2, pp. 178–185, 2018. View at: Publisher Site | Google Scholar
  49. M. Manco, V. Nobili, A. Alisi, N. Panera, and A. Handberg, “Arterial stiffness, thickness and association to suitable novel markers of risk at the origin of cardiovascular disease in obese children,” International Journal of Medical Sciences, vol. 14, no. 8, pp. 711–720, 2017. View at: Publisher Site | Google Scholar
  50. A. Wykretowicz, A. Rutkowska, T. Krauze et al., “Pulse pressure amplification in relation to body fatness,” British Journal of Clinical Pharmacology, vol. 73, no. 4, pp. 546–552, 2012. View at: Publisher Site | Google Scholar
  51. M. R. Alfonso, R. L. Armentano, L. J. Cymberknop, A. R. Ghigo, F. M. Pessana, and W. E. Legnani, “A novel interpretation for arterial pulse pressure amplification in health and disease,” Journal of Healthcare Engineering, vol. 2018, 9 pages, 2018. View at: Publisher Site | Google Scholar
  52. A. P. Avolio, L. M. Van Bortel, P. Boutouyrie et al., “Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data,” Hypertension, vol. 54, no. 2, pp. 375–383, 2009. View at: Publisher Site | Google Scholar
  53. L. Van Bortel, S. Laurent, P. Boutouyrie et al., “Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity,” Journal of Hypertension, vol. 30, no. 3, pp. 445–448, 2012. View at: Publisher Site | Google Scholar

Copyright © 2019 Ioana Mozos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

805 Views | 262 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.